EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma

Christopher A Barker, Suzanne Dufault iD, Sarah T Arron iD, Alan L Ho iD, Alain P Algazi iD, Lara A Dunn, Audrey A Humphries iD, Carter Hultman, Ming Lian, P Daniel Knott, Sue S Yom iD

Journal of Clinical Oncology · 01.07.2024 · 42 (19) · 2327-2335

DOI: 10.1200/jco.23.01708 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2024. Verfasst von Christopher A Barker und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Anilides, Pyridines, Basal Cell Carcinoma, Skin Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that may radiosensitize BCC. We evaluated the combination of vismodegib and RT for patients with LA BCC. METHODS In this multicenter, single-arm, phase II study, patients with unresectable LA BCC received 12 weeks of induction vismodegib, followed by 7 weeks of concurrent vismodegib and RT. The primary end point was LRC rate at 1 year after the end of treatment. Secondary end points included objective response, progression-free survival (PFS), overall survival (OS), safety, and patient-reported quality of life (PRQOL). RESULTS Twenty-four patients received vismodegib; five were unable to complete 12 weeks of induction therapy. LRC was achieved in 91% (95% CI, 68 to 98) of patients at 1 year. The response rate was 63% (95% CI, 38 to 84) after induction vismodegib and 83% (95% CI, 59 to 96) after concurrent vismodegib and RT. With a median follow-up of 5.7 years, 1-year PFS and OS rates were 100% and 96%, and at 5 years PFS and OS rates were 78% and 83%, respectively. Distant metastasis or BCC-related death has not been observed. The most frequent treatment-related adverse events (AEs) were dysgeusia, fatigue, and myalgias occurring in 83%, 75%, and 75% of patients. No grade 4 to 5 treatment-related AEs occurred. PRQOL demonstrated clinically meaningful improvements in all subscales, with emotions and functioning improvements persisting for a year after the end of treatment. CONCLUSION In patients with unresectable LA BCC, the combination of vismodegib and RT yielded high rates of LRC and PFS and durable improvements in PRQOL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesPyridinesBasal Cell CarcinomaSkin NeoplasmsHumansFemaleMaleAgedMiddle AgedAged, 80 and overQuality of LifeAdultChemoradiotherapyProgression-Free Survival

Substanzen

HhAntag691AnilidesPyridines

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA.
  • Department of Dermatology, University of California San Francisco, San Francisco, CA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Department of Radiation Oncology, University of California San Francisco, San Francisco, CA.

ORCID-Profile: Suzanne Dufault, Sarah T Arron, Alan L Ho, Alain P Algazi, Audrey A Humphries, Sue S Yom

Förderung

  • NCI NIH HHS

Zitieren

APA

Barker, C. A., Dufault, S., Arron, S. T., Ho, A. L., Algazi, A. P., Dunn, L. A., Humphries, A. A., Hultman, C., Lian, M., Knott, P. D., & Yom, S. S. (2024). Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma. Journal of Clinical Oncology, 42(19), 2327-2335. https://doi.org/10.1200/jco.23.01708

Vancouver

Barker CA, Dufault S, Arron ST, Ho AL, Algazi AP, Dunn LA, et al. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma. Journal of Clinical Oncology. 2024;42(19):2327-2335. doi:10.1200/jco.23.01708

BibTeX
@article{Barker2024,
  author = {Barker, Christopher A and Dufault, Suzanne and Arron, Sarah T and Ho, Alan L and Algazi, Alain P and Dunn, Lara A and Humphries, Audrey A and Hultman, Carter and Lian, Ming and Knott, P Daniel and Yom, Sue S},
  title = {Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {19},
  pages = {2327--2335},
  doi = {10.1200/jco.23.01708}
}
Kostenlos starten →